These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 15847660)
21. Platelet-released proteins as molecular markers for the activation process. Walz DA Semin Thromb Hemost; 1984 Oct; 10(4):270-9. PubMed ID: 6240116 [TBL] [Abstract][Full Text] [Related]
22. A reliable plasma marker of platelet activation: does it exist? Gurney D; Lip GY; Blann AD Am J Hematol; 2002 Jun; 70(2):139-44. PubMed ID: 12111787 [TBL] [Abstract][Full Text] [Related]
23. Enhanced release of platelet factor 4 into the circulation in patients with atopic eczema/dermatitis syndrome. Kasperska-Zajac A; Rogala B; Nowakowski M Rocz Akad Med Bialymst; 2003; 48():128-30. PubMed ID: 14737958 [TBL] [Abstract][Full Text] [Related]
24. Performance evaluation of cytometric bead assays for the measurement of lung cytokines in two rodent models. Young SH; Antonini JM; Roberts JR; Erdely AD; Zeidler-Erdely PC J Immunol Methods; 2008 Feb; 331(1-2):59-68. PubMed ID: 18089291 [TBL] [Abstract][Full Text] [Related]
25. Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system. St Ledger K; Agee SJ; Kasaian MT; Forlow SB; Durn BL; Minyard J; Lu QA; Todd J; Vesterqvist O; Burczynski ME J Immunol Methods; 2009 Oct; 350(1-2):161-70. PubMed ID: 19732777 [TBL] [Abstract][Full Text] [Related]
27. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Al-Tamimi M; Mu FT; Moroi M; Gardiner EE; Berndt MC; Andrews RK Platelets; 2009 May; 20(3):143-9. PubMed ID: 19437330 [TBL] [Abstract][Full Text] [Related]
28. Development of enzyme-linked immunosorbent assay for human cardiac myosin light chain I. Miyazaki S; Hamaoki M; Nagata A Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):323-6. PubMed ID: 16082420 [TBL] [Abstract][Full Text] [Related]
29. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Mattioli AV; Bonetti L; Zennaro M; Ambrosio G; Mattioli G Am Heart J; 2009 Mar; 157(3):589-95. PubMed ID: 19249435 [TBL] [Abstract][Full Text] [Related]
30. Measurement of beta-thromboglobulin and platelet factor 4 to follow up patients with artificial heart valves. Bellon JL; Castellanos C; Acevedo L; Amiral J Semin Thromb Hemost; 1993; 19 Suppl 1():178-82. PubMed ID: 8362264 [TBL] [Abstract][Full Text] [Related]
31. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226 [TBL] [Abstract][Full Text] [Related]
32. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Lin L; Conlan MG; Tessman J; Cimino G; Porter S Transfusion; 2005 Oct; 45(10):1610-20. PubMed ID: 16181212 [TBL] [Abstract][Full Text] [Related]
34. Interactions of platelet factor 4 with the vessel wall. Sachais BS; Higazi AA; Cines DB; Poncz M; Kowalska MA Semin Thromb Hemost; 2004 Jun; 30(3):351-8. PubMed ID: 15282658 [TBL] [Abstract][Full Text] [Related]
35. Development of a sensitive enzyme immunoassay for anti-Müllerian hormone and the evaluation of potential clinical applications in males and females. Al-Qahtani A; Muttukrishna S; Appasamy M; Johns J; Cranfield M; Visser JA; Themmen AP; Groome NP Clin Endocrinol (Oxf); 2005 Sep; 63(3):267-73. PubMed ID: 16117813 [TBL] [Abstract][Full Text] [Related]
36. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726 [TBL] [Abstract][Full Text] [Related]
37. Proteomic analysis of supernatant from pooled buffy-coat platelet concentrates throughout 7-day storage. Glenister KM; Payne KA; Sparrow RL Transfusion; 2008 Jan; 48(1):99-107. PubMed ID: 17894789 [TBL] [Abstract][Full Text] [Related]
38. In vivo recovery of human platelets in severe combined immunodeficient mice as a measure of platelet damage. Piper JT; Gelderman MP; Vostal JG Transfusion; 2007 Aug; 47(8):1540-9. PubMed ID: 17655600 [TBL] [Abstract][Full Text] [Related]
39. High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Alamdari DH; Kostidou E; Paletas K; Sarigianni M; Konstas AG; Karapiperidou A; Koliakos G Free Radic Biol Med; 2005 Nov; 39(10):1362-7. PubMed ID: 16257645 [TBL] [Abstract][Full Text] [Related]
40. An ELISA for measuring tumour necrosis factor alpha in rat plasma. Campbell GR; Magee D; Kennedy A; Rowlands BJ; Halliday MI Eur Cytokine Netw; 1997 Mar; 8(1):97-102. PubMed ID: 9110155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]